Press Releases #
NeuroCytonix Authorized by COFEPRIS to Launch Neuro-Restorative Program in Mexico #
6 NOV 2026
NeuroCytonix, Inc. announced that its subsidiary, NeuroCytonix México S.A. de C.V., has received authorization from the Mexican regulatory authority, COFEPRIS, to operate medical centers offering neuro-restorative programs for neurological conditions. This marks an important step in providing a complementary approach for cerebral palsy and other neurological conditions. All NeuroCytonix programs remain investigational until full regulatory approvals are obtained.
NeuroCytonix Hosts Forum on Autism Research and Innovation #
11 MAR 2026
NeuroCytonix hosted an inspiring forum in Washington DC, bringing together parents, researchers, and advocates to explore cutting-edge innovations in autism research. The event spotlighted the company’s Functional Neurogenesis Stimulation (FNS) technology, currently being studied for its potential to support brain repair and improve communication and learning in individuals with autism spectrum disorder. Highlights included expert insights, personal testimonials, and a look at upcoming clinical trials—offering hope and fostering meaningful conversations about the future of autism care.
NeuroCytonix Launches a Clinical Trial Studying Its NeuroCytotron Protocol for Autism #
03 JUL 2024
NeuroCytonix, Inc., announced that on May 27, 2024, its subsidiary NeuroCytonix Mexico received a regulatory approval letter from the ethical, scientific, and safety committees of Hospital La Mision in Monterrey, Mexico, to launch a clinical trial on autism. The study is aptly named "Preliminary Efficacy and Feasibility of Using the NeuroCytotron to Treat Autism Spectrum Disorder: A Pilot Study."
NeuroCytonix Completes Clinical Trial of its NeuroCytotron Treatment of Cerebral Palsy #
30 JAN 2023
NeuroCytonix, Inc. announced that on January 19, 2023, its subsidiary NeuroCytonix Mexico received a regulatory acknowledgment letter from the Mexican regulatory authority COFEPRIS – ref/memorandum number 223300ES450795/2023 – following the presentation of NeuroCytonix's final report on its clinical trial on Cerebral Palsy NCX-CP-01. The acknowledgment represents the legal and formal conclusion of the clinical trial, according to the methodology authorized by COFEPRIS. The resolution of the NCX-CP-01 clinical trial provides safety and efficacy data on the investigational NeuroCytotron treatment of Cerebral Palsy.
NeuroCytonix Mexico Clinical Research Center #
Discover the future of medical research at our state-of-the-art clinical research center.
